A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet.

Conditions

Pancreatic Ductal Adenocarcinoma
Non-small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL: Durvalumab
BIOLOGICAL: Oleclumab

Sponsor

University Health Network, Toronto

Collaborators

[object Object]